Joint Formulary & PAD

Upadacitinib - Rheumatoid arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Upadacitinib
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Immunomodulator, Protein Kinase Inhibitor, JAK inhibitor, Janus Kinase, NICE TA, JAKI
Brand Names Include :
Rinvoq
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
6

Other Indications

Below are listed other indications that Upadacitinib is used to treat.

Committee Recommendations (3)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends Upadacatinib as a treatment option for the treatment of moderate  Rheumatoid Arthritis in line with NICE TA744

Upadacatinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA744.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends Upadacatinib as a treatment option for the treatment of  severe Rheumatoid Arthritis in line with NICE TA665

Upadacatinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA665.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

The updated Rheumatoid Arthritis high cost DMARDs treatment pathway is attached below